drugset / Trial / NCT00024063

SU006668 in Treating Patients With Advanced Solid Tumors

NCT00024063 ↗

Treatment

Summary

RATIONALE: Drugs such as SU006668 may stop the growth of solid tumors by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU006668 in treating patients who have advanced solid tumors.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Orantinib Small molecule — Oral